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Available online xxxxFibroblast growth factor-23 (FGF23) is a bone-derived hormone protecting against the potentially deleterious ef-
fects of hyperphosphatemia by suppression of phosphate reabsorption and of active vitamin D hormone synthe-
sis in the kidney. The kidney is one of the main target organs of FGF23 signaling. The purpose of this review is to
highlight the recent advances in the area of FGF23-Klotho signaling in the kidney. During recent years, it has be-
come clear that FGF23 acts independently on proximal and distal tubular epithelium. In proximal renal tubules,
FGF23 suppresses phosphate reabsorption by a Klotho dependent activation of extracellular signal-regulated ki-
nase-1/2 (ERK1/2) and of serum/glucocorticoid-regulated kinase-1 (SGK1), leading to phosphorylation of the
scaffolding protein Na+/H+ exchange regulatory cofactor (NHERF)-1 and subsequent internalization and degra-
dation of sodium-phosphate cotransporters. In distal renal tubules, FGF23 augments calcium and sodium reab-
sorption by increasing the apical membrane expression of the epithelial calcium channel TRPV5 and of the
sodium-chloride cotransporter NCC through a Klotho dependent activation of with-no-lysine kinase-4
(WNK4). In proximal and distal renal tubules, FGF receptor-1 is probably the dominant FGF receptor mediating
the effects of FGF23 by forming a complex with membrane-bound Klotho in the basolateral membrane. The
newly described sodium- and calcium-conserving functions of FGF23 may have major implications for the path-
ophysiology of diseases characterized by chronically increased circulating FGF23 concentrations such as chronic
kidney disease.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Genetic studies inpatientswithautosomaldominanthypophosphatemic
rickets led to the discovery of ﬁbroblast growth factor-23 (FGF23) in the
year 2000 [1]. At the time of its discovery the function of FGF23 in healththophysiology and Biophysics,
dicine Vienna, Veterinärplatz 1,
. Erben).
. This is an open access article under
drukhova, FGF23-Klotho sigand disease was still unclear. However, follow-up studies soon uncov-
ered that FGF23 is a phosphaturic hormone, downregulating the
luminal membrane abundance of sodium phosphate co-transporters
(NaPi) in renal proximal tubular epithelium [2–4]. Lower membrane
abundance of phosphate-transporting molecules in the proximal neph-
ron leads to reduced phosphate reabsorption from urine, and, thus, to
increased urinary phosphate excretion. Excessive amounts of intact
FGF23 in the blood stream such as those found in patients with autoso-
mal dominant hypophosphatemic rickets, X-linked hypophosphatemic
rickets (XLH) or tumor-induced osteomalacia lead to renal phosphatethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
naling axis in the kidney, Bone (2016), http://dx.doi.org/10.1016/
2 R.G. Erben, O. Andrukhova / Bone xxx (2016) xxx–xxxwasting and impaired bone mineralization [5]. In addition to its
phosphaturic action, FGF23 also down-regulates renal proximal tubular
expression of 1α-hydroxylase, the rate-limiting enzyme in the synthesis
of the vitamin D hormone, 1α,25-dihydroxyvitamin D3 [1,25(OH)2D]
[2–4]. Therefore, FGF23not only increases urinary excretion of phosphate,
it at the same time indirectly suppresses intestinal phosphate absorption
by down-regulating the production of 1,25(OH)2D. The net effect of both
hormonal actions is to lower circulating phosphate concentrations,
safeguarding against the deleterious effects of hyperphosphatemia.
Although other tissues may also contribute to circulating intact
FGF23 concentrations [6], bone is probably themajor source for circulat-
ing FGF23 under physiological circumstances in vivo [5]. There is good
evidence that FGF23 is secreted by both osteocytes and osteoblasts in
bone [7,8]. Bony FGF23 secretion is stimulated by 1,25(OH)2D and by in-
creased extracellular phosphate, thus forming a feedback loop between
kidney and bone [5,9,10].
αKlotho (Klotho) is named after the Greek goddess spinning the
thread of life, andwas discovered as a gene regulating aging [11]. Klotho
is a single pass transmembrane protein with a large extracellular do-
main, consisting of the two domainsKL1 andKL2,which share sequence
homologies with family I β-glycosidases [11]. Klotho exists in three
isoforms, a transmembrane form, a shed soluble form consisting of
KL1 and KL2 which is produced from transmembrane Klotho by protease-
mediated cleavage of the extracellular domain of Klotho, and a truncat-
ed soluble form consisting of KL1 produced by alternative splicing of
KlothomRNA [12]. Klotho is expressed in several tissues. However, the
main sites of Klotho expression are the kidney (distal and proximal
renal tubules), the choroid plexus in the brain, and parathyroid glands
[11,13–17]. Because the phenotype of mice with a kidney-speciﬁc abla-
tion of Klotho is almost identical to the phenotype of global Klotho
knockoutmice, the kidney is probably themost important site of Klotho
expression, and also themajor source of circulating soluble Klotho [18].
The functional role of Klotho is still a matter of controversy. Klotho has
been proposed to function as a hormone in its soluble forms, as a glyco-
sidase, and as a co-receptor for FGF23 in its transmembrane form [12].
In the current review about renal FGF23-Klotho signaling, we naturally
focus on the latter function.
FGFs signal through 4 different FGF receptors (FGFR), FGFR1-4,
which are all tyrosine kinase receptors. Activation of FGFRs through li-
gand binding and dimerization leads to phosphorylation of downstream
signaling molecules [19]. Endocrine FGFs such as FGF23 do not have a
heparan sulfate binding domain, and require co-expression of mem-
brane-bound Klotho for high afﬁnity binding to ubiquitously expressed
FGFRs in target tissues [14,20]. For example, the FGFR1c/Klotho receptor
complex has a ~20-fold higher binding afﬁnity for FGF23 compared
with FGFR1c alone [21]. As described below, it is currently not entirely
clear which FGFRs are responsible for mediating the actions of FGF23
in different tissues. Nevertheless, there is ample evidence that signaling
through the FGFR1c/Klotho complex plays a pivotal role formany of the
hormonal actions of FGF23 [14]. However, binding of Klotho to FGFR3
and 4 has also been reported [20].
The purpose of this review is to highlight the recent advances in the
area of FGF23-Klotho signaling in the kidney. FGF23-independent ef-
fects of Klotho are not covered by this review. During recent years, sig-
niﬁcant progress has been made in the further characterization of
FGF23-mediated signaling pathways in proximal and distal renal tu-
bules, and new functions of FGF23 with potential major pathophysio-
logical implications have been found.
1.1. Proximal tubular phosphate re-uptake
Unlike other minerals such as calcium, magnesium, potassium, sodi-
um, or chloride, the endocrine regulation of phosphate reabsorption in
the kidney takes place in the proximal renal tubule, and involves the
regulation of the luminal membrane abundance of phosphate-
transporting molecules in the epithelium [22]. Parathyroid hormonePlease cite this article as: R.G. Erben, O. Andrukhova, FGF23-Klotho sig
j.bone.2016.09.010(PTH), the principal phosphaturic hormone, downregulates membrane
expression of the key sodium-phosphate cotransporter, NaPi-2a, by a
signaling cascade leading to phosphorylation of Na+/H+ exchange reg-
ulatory cofactor (NHERF)-1 as a ﬁnal step. Because the scaffolding pro-
tein NHERF-1 is necessary to anchor NaPi-2a in the cell membrane,
phosphorylation of NHERF-1 leads to internalization and degradation
of NaPi-2a [23,24].
Based on the work of Shimada and coworkers [2] and on mouse
models characterized by transgenic overexpression of FGF23 [25,26], it
became clear soon after its discovery that FGF23 is a phosphaturic hor-
mone, suppressing apical membrane expression of NaPi-2a and NaPi-2c
in renal proximal tubules. However, themolecularmechanismunderly-
ing this effect remained elusive for many years. Studies using in situ hy-
bridization [11] and immunohistochemistry employing a monoclonal
antibody directed against the human KL1 domain [27] suggested
that the main site of Klotho expression in the kidney is the distal
renal tubule. In addition, the earliest increase in extracellular
signal-regulated kinase (ERK) phosphorylation after injection of
FGF23 into mice occurs in distal renal tubules [28]. These ﬁndings
led to the hypothesis that binding of blood-borne FGF23 to distal
tubular cells generates an unknown paracrine or endocrine signal
which in turn acts on proximal tubular epithelium to suppress phos-
phate reabsorption [29,30]. However, this putative signaling mole-
cule has never been found.
Using an antibody speciﬁcally directed against the membrane-
bound Klotho isoform, we showed by immunohistochemistry and by
Western blotting analysis of proximal and distal renal tubules harvested
by laser capture microdissection that protein expression of membrane-
bound Klotho is actually similar in proximal and distal tubules in the
mouse [17]. It is likely that the discrepant ﬁndings regarding Klotho ex-
pression in themurine kidney [17,27] can be explained by differences in
the anti-Klotho antibodies used which detect different isoforms of the
protein. Extending the demonstration of the presence of the co-receptor
Klotho in proximal renal tubules, we further showed that FGF23 can di-
rectly activate ERK1/2 and serum/glucocorticoid-regulated kinase-1
(SGK1) in isolated proximal tubular segments in a Klotho dependent
fashion [17]. Activation of SKG1 in turn leads to phosphorylation of
NHERF-1, and subsequent downregulation of themembrane expression
of NaPi-2a (Fig. 1). Phosphorylation of NHERF-1 appears to be essential
for the phosphaturic action of FGF23, because proximal tubular cells
from NHERF-1 null mice are resistant to the FGF23-mediated inhibition
of phosphate transport [31]. There is indirect evidence that Janus kinase
3 (JAK3) may somehow be involved in FGF23 signaling, because
Jak3−/−mice show renal phosphatewasting and increased serum levels
of Fgf23 and 1,25(OH)2D, suggesting renal resistance to the
phosphaturic effect of Fgf23 [32]. In addition, phosphate uptake in
Xenopus oocytes was further stimulated when JAK3 was co-expressed
together with NaPi-2a [32]. Collectively, these ﬁndings demonstrate
that the phosphaturic hormones PTH and FGF23 share the common tar-
get NHERF-1 in the regulation of phosphate transport in proximal tubu-
lar epithelium [17,31]. The overlap between the PTH and FGF23
signaling pathways may also explain the clinical ﬁnding that the
phosphaturic effect of FGF23 is decreased in patientswith hypoparathy-
roidism [33–35], suggesting that basal levels of circulating PTH are re-
quired for efﬁcient FGF23 signaling in humans. Vice versa, absence of
Fgf23 signaling leads to renal PTH resistance in mice [36].
Our ﬁnding that the phosphaturic effect of FGF23 is based on a direct
action on proximal tubules is strongly supported by two recent reports:
i) Han and coworkers [37] showed that mice with a speciﬁc deletion of
Fgfr1 in proximal renal tubules are characterized by hyperphosphatemia
and show resistance to the phosphaturic effect of FGF23. ii) Ide and
coworkers [38] reported that mice with a speciﬁc deletion of Klotho in
proximal tubuleswere unable to increase renal phosphate excretion in re-
sponse to a high phosphate diet. The study by Han et al. [37] also sheds
light on the question which FGF receptor is mainly mediating the
phosphaturic actions of FGF23 signaling. Proximal tubular epithelialnaling axis in the kidney, Bone (2016), http://dx.doi.org/10.1016/
Fig. 1. FGF23-Klotho signaling in the kidney. In proximal renal tubules, blood-borne FGF23 binds to a receptor complex consisting of FGFRs andαKlotho (Klotho), and activates a signaling
cascade involving ERK1/2 and SGK1. SGK1 in turn phosphorylates NHERF-1, leading to internalization and degradation of NaPi-2a. FGF23 signalingmay also involve Janus kinase-3 (JAK3).
PTHbinds to the PTH receptor (PTHR), leading to activation of PKAand PKC, and subsequent phosphorylation of NHERF-1. FGF23- and PTH-inducedphosphorylation ofNHERF-1 decreases
the membrane abundance of NaPi-2a, and leads to increased urinary phosphate excretion. The FGF23 signaling-induced mechanisms downstream of ERK1/2 which suppress the
transcription of 1α-hydroxylase in proximal renal tubules are unknown. In distal renal tubules, FGF23 circulating in blood binds to the FGFR-Klotho receptor complex, and activates
ERK1/2, SGK1, and the WNK1/4 complex. Activation of WNK signaling increases the luminal membrane abundance of glycosylated TRPV5 and of NCC, leading to increased distal
tubular calcium and sodium reabsorption. PKA, protein kinase A; PKC, protein kinase C.
3R.G. Erben, O. Andrukhova / Bone xxx (2016) xxx–xxxcells express FGFR1, 3, and 4, but not 2 [17,39]. Since conditional ablation
of Fgfr1 in proximal renal tubules largely blunts the hypophosphatemic
action of FGF23 [37], FGFR1 is probably the predominant receptor respon-
sible for the FGF23-mediated increase in urinary phosphate excretion in
vivo, conﬁrming earlier studies which compared the hypophosphatemic
action of FGF23 in global Fgfr4 or Fgfr3 deﬁcient mice and kidney speciﬁc
Fgfr1 knockoutmice [39]. However, ablation of both Fgfr1 and Fgfr4 is nec-
essary to completely abolish the phosphaturic action of FGF23 in mice
[40], suggesting that FGFR4 also plays some, albeit minor role for
FGF23-induced regulation of phosphate co-transporters in the kidney in
vivo.
It is well known that FGF23 suppresses the apical membrane abun-
dance of both NaPi-2a and NaPi-2c in vivo [3,25,26]. It has been shown
inmicewith a kidney-speciﬁc ablation of NaPi-2c that the phosphaturic
action of FGF23 is mainly determined by downregulation of the apical
membrane abundance of NaPi-2a, with NaPi-2c playing only a minor
role [41]. In addition, the absence of renal NaPi-2c does not seem to be
important for the control of phosphate homeostasis under physiological
conditions inmice [41]. In contrast, humanswith loss-of-functionmuta-
tions in NaPi-2c are characterized by hypophosphatemia and renal
phosphatewastingwhich obviously cannot be balanced by counter-reg-
ulatory changes in NaPi-2a [42]. Furthermore, in contrast to mice, loss-
of-function mutations in NaPi-2a do not invariably lead to
hypophosphatemia and renal phosphate wasting in humans [43].
Therefore, species speciﬁc differences in the importance of phosphate
transporters in the kidney need to be considered.Please cite this article as: R.G. Erben, O. Andrukhova, FGF23-Klotho sig
j.bone.2016.09.010In conclusion, FGF23 suppresses phosphate reabsorption in renal
proximal tubular epithelium by a Klotho dependent, predominantly
FGFR1-mediated signaling mechanism, involving activation of ERK1/2
and of SGK1 which in turn leads to phosphorylation of NHERF-1
(Fig. 1). It is currently unclear whether NHERF-1 is a direct target of
SGK1, or whether SKG1 leads to activation of additional downstream
kinases which subsequently phosphorylate NHERF-1.
1.2. Proximal tubular vitamin D hormone synthesis
The kidney is the major source of circulating 1,25(OH)2D under
physiological circumstances [44]. The key enzyme responsible for
1,25(OH)2D production, 1α-hydroxylase (CYP27B1), is predominantly
expressed in proximal tubular cells [45], and is strictly regulated by
PTH, FGF23, and 1,25(OH)2D itself [46]. Expression and activity of
renal 1α-hydroxylase is suppressed by FGF23 and 1,25(OH)2D,
and stimulated by PTH [46]. The essential function of FGF23-Klotho sig-
naling for the regulation of renal 1α-hydroxylase is illustrated by the
fact that despite hypercalcemia and suppressed PTH, 1α-hydroxylase
expression remains inappropriately high in Klotho and Fgf23 deﬁcient
mice [47–49]. Therefore, in the absence of the suppressive action
of FGF23-Klotho signaling on renal 1α-hydroxylase expression, the
complex system involved in the regulation of this enzyme fails.
Klotho−/− and Fgf23−/−mice are characterized by unleashed produc-
tion of the active vitamin D hormone, leading to hypercalcemia and
hyperphosphatemia [47–50]. The sequelae of hypercalcemia andnaling axis in the kidney, Bone (2016), http://dx.doi.org/10.1016/
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ture death, ectopic calciﬁcations, organ atrophy, and osteomalacia [11,
48,50]. In analogy to the mouse models, loss-of-function mutations in
KLOTHO [51] or FGF23 [52] in humans cause tumoral calcinosis, a disease
associated with increased 1,25(OH)2D serum levels, hypercalcemia,
hyperphosphatemia, and calciﬁcations in soft tissues and blood vessels.
Whether FGF23 signaling also directly regulates 24-hydroxylase
(CYP24A1), the most important enzyme initiating vitamin D degrada-
tion [53], in proximal renal tubules is a controversial issue. Our labora-
tory found unchanged CYP24A1 mRNA expression in the kidney of
4-week-old Klotho−/− and Fgf23−/− mice, relative to WT mice [49].
However, others reported increased CYP24A1 mRNA levels in kidneys
of Fgf23−/−mice older than 3weeks [48]. Moreover, injection of recom-
binant FGF23 intoWTmice suppresses renal 1α-hydroxylasemRNA ex-
pression and at the same time upregulates 24-hydroxylase mRNA
expression [3]. Therefore, FGF23 signalingmay have direct, opposing ef-
fects on the regulation of renal 1α- and 24-hydroxylase. However, be-
cause 1,25(OH)2D is a strong inducer of 24-hydroxylase in all tissues
[53], it is difﬁcult to separate direct effects of FGF23 signaling from indi-
rect effects caused by altered 1,25(OH)2D production in vivo. Notably,
treatment with recombinant FGF23 suppressed renal 1α-hydroxylase
mRNA expression in VDR-ablated mice characterized by deﬁcient vita-
min D signaling, but failed to upregulate 24-hydroxylase expression
[4]. Another study in VDR-ablated mice also came to the conclusion
that the FGF23-induced regulation of 24-hydroxylase is VDR dependent
[54]. However, a potential caveat in the studies using VDR knockout
mice is that 24-hydroxylase is profoundly suppressed in the absence
of vitamin D signaling, and PTH, another suppressor of 24-hydroxylase,
is usually elevated in thesemice. Taken together, there is solid evidence
that FGF23 signaling regulates 1α-hydroxylase in a 1,25(OH)2D inde-
pendent manner [48]. Whether FGF23 is able to regulate 24-hydroxy-
lase in a vitamin D independent fashion still awaits further
clariﬁcation. In this regard, more conclusive evidence will probably
come from appropriate in vitro systems. So far, information from in
vitro experiments is scarce, but in cultured murine proximal tubular
cells, FGF23 had only weak and inconsistent effects on 24-hydroxylase
expression [55].
The similarities between the phenotypes of Klotho−/− and Fgf23−/−
mice strongly suggest that FGF23 regulates 1α-hydroxylase expression
by a Klotho-dependent mechanism. This notion has recently been chal-
lenged by a report showing that mice characterized by a speciﬁc abla-
tion of Klotho in proximal renal tubules had unchanged 1,25(OH)2D
levels under basal conditions [38]. The recombination efﬁciency in prox-
imal tubules was between 50 and 95% for the different Cre mouse lines
in the latter study [38]. Therefore, residual proximal tubular Klotho ex-
pression may account for the discrepancies between the phenotypes of
mice with global vs. proximal tubular-speciﬁc Klotho ablation.
The intracellular signalingmechanisms involved in the FGF23-medi-
ated suppression of renal 1α-hydroxylase are only partially known. In
Hypmice, amousemodel of the human disease XLHwhich is character-
ized by increased endogenous Fgf23 secretion, it was shown that the el-
evated serum Fgf23 levels are correlated with increased ERK1/2
signaling, and that blockade of ERK1/2 in the kidney of Hyp mice im-
proves hypophosphatemia, 1,25(OH)2D deﬁciency, and the skeletal
mineralization defects [56,57]. The transcription factor egr-1 is a down-
stream target of FGF23-induced ERK1/2 activation [14]. However, a re-
cent study using egr-1 null (egr-1−/−) and Hyp/egr-1−/− mice
suggested that egr-1 signaling is important for Fgf23-mediated changes
in renal phosphate homeostasis, but not for 1,25(OH)2D metabolism
[58]. As mentioned above, Jak3−/−mice are characterized by increased
serum 1,25(OH)2D levels as well as increased 1α-hydroxylase expres-
sion in the kidney [32]. Therefore, JAK3 may also be involved in the
FGF23-Klotho signaling axis regulating renal 1α-hydroxylase.
Regarding the FGF receptors responsible for the FGF23-mediated
suppression of renal 1α-hydroxylase, it has recently been shown that
treatment with recombinant FGF23 fails to induce a decrease in serumPlease cite this article as: R.G. Erben, O. Andrukhova, FGF23-Klotho sig
j.bone.2016.09.0101,25(OH)2D levels in mice with a conditional deletion of Fgfr1 in proxi-
mal tubules, indicating that, similar to the suppression of phosphate re-
absorption by FGF23, FGFR1 may be the most important FGFR for the
FGF23-mediated regulation of 1,25(OH)2D production in proximal tu-
bules [37]. In contrast, earlier studies using kidney-speciﬁc conditional
Fgfr1 knockout mice, as well as global Fgfr3−/− and Fgfr4−/− mutants
treated with recombinant FGF23 showed a similar suppression of
serum 1,25(OH)2D levels by FGF23 in all three knockout lines [39], sug-
gesting that more than one FGFR may mediate the effect of FGF23 on
1,25(OH)2D metabolism. Later studies by the same group yielded con-
ﬂicting results: one study showed that recombinant FGF23 had no effect
on serum1,25(OH)2D levels in global Fgfr3−/−/Fgfr4−/− compoundmu-
tants [59], whereas in a second study circulating 1,25(OH)2D levels
were elevated and the FGF23-induced suppression of 1,25(OH)2D
serum levels was blunted in compound mutant mice characterized by
a kidney-speciﬁc conditional Fgfr1 knockout and a global deletion of
Fgfr4 [40]. Experiments in which Fgfr3 and Fgfr4 were deleted in Hyp
mice also suggested that the FGF23-induced suppression of renal hy-
droxylase expression is mediated through a combination of FGFR1,
FGFR3, and FGFR4 signaling [60]. Collectively, the available data suggest
that FGF23 suppresses renal 1α-hydroxylase expression by a Klotho de-
pendent signaling mechanism involving FGFR1, 3 and 4. As mentioned
above, it is not entirely clear whether Klotho associates with FGFR3
and 4 under physiological conditions. It is well established that FGF23
signaling activates ERK1/2. However, further details of the intracellular
signaling pathways downstream of ERK1/2 are not known (Fig. 1).
What is currently known about FGF23 signaling in proximal tubular
epithelium is schematically shown in Fig. 1. So far, the FGF23-induced
intracellular signaling cascades regulating the membrane abundance
of phosphate transporters as well as the expression of 1α-hydroxylase
have only partially been characterized. It is an important goal to im-
prove our understanding of the molecular mechanisms involved in
FGF23 signaling in proximal tubular epithelium, because better insight
in the signaling mechanisms involved may eventually lead to new pos-
sibilities in the treatment of phosphate-wasting disorders and of disor-
ders involving alterations in renal 1,25(OH)2D production.
1.3. Distal tubular calcium and sodium transport
Although it has long been known that Klotho is expressed in distal
tubular epithelium [11], and that injection of FGF23 activates ERK1/2
within minutes in distal tubules in vivo [28], it was previously believed
that FGF23 exclusively regulates phosphate reabsorption and
1,25(OH)2D synthesis in proximal renal tubules. However, we recently
reported that FGF23 also has physiologically relevant direct effects on
distal tubular epithelium [61,62].
Calcium reabsorption from the urine is hormonally regulated in dis-
tal renal tubules by control of the apical membrane abundance and
openprobability of the epithelial calcium channel transient receptor po-
tential vannilloid-5 (TRPV5) [63]. Calcium entry into the epithelial cells
through the glycoprotein TRPV5 is the rate-limiting step in distal tubu-
lar transcellular calcium transport [63]. Based on our initial ﬁnding of
renal calcium wasting in compound mutants characterized by a com-
bined deﬁciency in Klotho or Fgf23 and a functioning VDR, we identiﬁed
FGF23 as a vitamin D independent regulator of TRPV5 in renal distal tu-
bules [61]. FGF23 signaling leads to activation of ERK1/2, SGK1, and
with-no-lysine kinase 4 (WNK4) in distal renal tubules, acting through
the FGFR/Klotho receptor complex [61].WNK kinases are key regulators
of intracellular transport of membrane proteins such as TRPV5, and act
as a complex ofWNK1, 3, and 4 [64–67]. We found that FGF23 is a pow-
erful regulator of TRPV5 expression and of calcium reabsorption in the
kidney. Injection of mice with recombinant FGF23 led to increased
membrane trafﬁcking and distinctly upregulated TRPV5membrane ex-
pression in distal renal tubules, together with profoundly reduced renal
calcium excretion [61]. The FGF23-induced regulation of TRPV5 mem-
brane abundance and calcium entry is a direct action on distal tubules,naling axis in the kidney, Bone (2016), http://dx.doi.org/10.1016/
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[61]. Taken together, our recent ﬁndings demonstrate that FGF23, simi-
lar to the other phosphaturic hormone PTH, also acts as a calcium-con-
serving hormone in the distal nephron. This notion has recently been
independently conﬁrmed: similar to our Klotho and Fgf23 loss-of-func-
tion models, conditional knockout mice with a speciﬁc deletion of
Fgfr1 in distal renal tubules are characterized by renal calcium wasting
[37].
Because WNK4 is also a key regulator of distal tubular membrane
abundance of the Na+:Cl− cotransporter NCC [68], the ﬁnding that
FGF23 signaling activates WNK4 in distal tubular epithelium prompted
us to examine FGF23-induced changes in renal sodium handling. NCC is
a key molecule for distal tubular sodium and chloride reabsorption, and
sodium reabsorption in the distal nephron is mainly regulated through
NCC and the epithelial sodium channel ENaC. We found that Fgf23 and
Klotho deﬁcient mice are characterized by lower distal tubular NCC ex-
pression, renal sodium wasting, lower blood volume, and hypotension
despite a counter-regulatory increase in aldosterone secretion and
ENaC expression [62]. Conversely, injection of recombinant FGF23 in
wildtype but not Klotho deﬁcient mice increased renal NCC expression,
and caused renal sodium retention, plasma expansion, increased blood
pressure, and heart hypertrophy [62]. Notably, co-treatment of FGF23-
treated mice with the NCC inhibitor chlorothiazide completely
prevented the FGF23-induced volume expansion, hypertension, and
heart hypertrophy [62].
An interesting observation in this contextwas that a low sodiumdiet
did not protect against, but actually aggravated the FGF23-induced hy-
pertension [62]. A low sodium diet increases aldosterone secretion,
which upregulates membrane abundance of NCC and ENaC in the distal
nephron through the SGK1 - WNK4 - STE20/SPS-1-related proline/ala-
nine-rich kinase (SPAK) signaling axis in an attempt to maximally con-
serve sodium [69–72]. Because aldosterone, similar to FGF23, also
activates SGK1 in distal renal tubules, FGF23 and aldosterone signaling
may have synergistic effects onNCC activation and volumehomeostasis.
The interaction between FGF23 and the renin-angiotensin-aldosterone-
system (RAAS) has recently been indirectly supported by a study show-
ing that FGF23 treatment interferes with the beneﬁcial effects of angio-
tensin receptor blockade in mice subjected to unilateral ureteral
obstruction as a model of renal ﬁbrosis [73].
The novel link between FGF23 and calciumaswell as sodiummetab-
olism may have major pathophysiological implications for diseases in
which FGF23 is chronically elevated such as in chronic kidney disease
(CKD). The calcium-conserving function of FGF23 may not have nega-
tive health consequences in XLH patients and Hypmice despite ex-
cessive FGF23 serum levels, because 1,25(OH)2D production is
suppressed and serum phosphate levels are low due to renal phos-
phate wasting. However, in CKD patients, the declining kidney
function leads to hyperphosphatemia und secondary hyperpara-
thyroidism. Hyperphosphatemia is an important risk factor for
vascular calciﬁcation and cardiovascular disease [74,75]. In this situa-
tion, the FGF23-mediated increase in renal-tubular calcium reabsorp-
tion may contribute to calcium retention and vascular calciﬁcation.
The recently reported positive association between aortic valve calciﬁ-
cation and serum FGF23 as well as serum PTH in patients with CKD
supports this line or argumentation [76].
Although we found increased renal sodium retention and slightly
higher blood pressure in Hyp mice than in WT controls despite lower
serum aldosterone [62], hypertension is not a common trait in XLH pa-
tients [77]. It is likely that the sodium-conserving effect of FGF23 can be
largely counterbalanced by decreased aldosterone secretion and RAAS
activity as long as kidney function is normal. Data about cardiovascular
function in XLH patients are scarce, but some studies reported a high in-
cidence of ventricular hypertrophy in XLH patients [77] which may re-
ﬂect chronically increased volume load. Whether aldosterone serum
levels are lower in XLH patients remains to be shown. In contrast, the
presence of renal disease may interfere with the ability of the body toPlease cite this article as: R.G. Erben, O. Andrukhova, FGF23-Klotho sig
j.bone.2016.09.010compensate chronic elevations in circulating FGF23. Driven by renal dis-
ease mechanisms, aldosterone levels are typically elevated in CKD pa-
tients due to activation of the RAAS [78]. Based on our data, increased
serum aldosteronemay further enhance the effects of FGF23 on sodium
retention, volume homeostasis, and blood pressure in CKD patients in
this situation. This mechanism may provide a tentative explanation
why circulating FGF23 is positively and dose-dependently associated
with mortality, CKD progression, left ventricular hypertrophy, and vas-
cular calciﬁcations in CKD patients [79–81]. It is also conceivable that
high phosphate diets may predispose to the development of hyperten-
sion in normal subjects due to phosphate-induced stimulation of
FGF23 secretion and subsequently increased renal sodium retention
and volume load.
In conclusion, it has recently been established that FGF23 not only
suppresses renal phosphate reabsorption in proximal renal tubules,
but also regulates renal calciumand sodiumhandling in the distal neph-
ron by activation of WNK signaling. Hence, FGF23 is not only a
phosphaturic, but also a calcium- and sodium-conserving hormone.
This novel paradigm is schematically shown in Fig. 1.
2. Conclusion
Recent advances in the ﬁeld of FGF23-Klotho signaling in the kidney
have shown that FGF23 acts independently on proximal and distal tubu-
lar epithelium. In proximal renal tubular epithelium, FGF23 suppresses
phosphate reabsorption by a Klotho dependent activation of ERK1/2
and SGK1, leading to phosphorylation of NHERF-1 and subsequent in-
ternalization and degradation of NaPi-2a. In distal renal tubules, FGF23
augments sodium and calcium reabsorption by increasing the apical
membrane expression of TRPV5 and NCC through a Klotho dependent
activation ofWNK4. In proximal and distal renal tubules, FGFR1 is prob-
ably the dominant FGF receptor mediating the renal effects of FGF23 by
forming a complex with membrane-bound Klotho in the basolateral
membrane. The newly described sodium- and calcium-conserving func-
tions of FGF23 may have major implications for the pathophysiology of
diseases characterized by chronically increased circulating FGF23 con-
centrations such as chronic kidney disease.
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